Patent Applications Filed for Psychedelic Drug Combinations
New filings explore mixing psychedelic compounds with a fatty acid derivative to potentially treat mental health conditions.
Updated on Sept. 23, 2026 in Substance Abuse
Live Poll
Do you trust that combining psychedelic compounds with other drugs will create safer mental health treatments?
NeuroThera Labs has published three U.S. patent applications for combinations of psychedelic compounds, including LSD, ketamine, and ibogaine, with PEA technology. These filings aim to develop new therapeutic approaches for conditions such as depression, PTSD, and substance use disorders.
Why it matters
These filings represent a shift in exploring how non-psychedelic compounds might interact with psychedelics to refine or enhance potential neuropsychiatric treatments. This expansion of intellectual property is intended to support the development of novel therapeutic options for patients with treatment-resistant conditions.
The U.S. patent office published three new applications covering novel combinations of psychedelic substances with N-acylethanolamines, following an existing application for an MDMA combination. These applications are early-stage intellectual property developments rather than clinical study results.
The players
NeuroThera Labs
A biotech company focused on developing therapies for neuropsychiatric conditions through pharmaceutical collaborations.
Clearmind Medicine
A psychedelic medicine development company that maintains an ongoing research collaboration with NeuroThera Labs.
The details
The technology involves pairing psychedelic compounds with N-acylethanolamines (PEA), which are fatty acid derivatives. By combining these, researchers aim to create novel therapeutic approaches for complex neuropsychiatric conditions. The intellectual property is part of a collaborative portfolio between NeuroThera Labs and Clearmind Medicine.
Timeline
September 23, 2026: Three U.S. patent applications for drug combinations were published.
April 29, 2026: SciSparc filed an Annual Report on Form 20-F.
Health Landscape
These patent applications sit within the broader effort to expand the utility of psychedelic-assisted therapies through chemical modification or combination strategies. This trend reflects an evolution in medical science aimed at potentially minimizing adverse effects or enhancing the therapeutic outcomes of traditional psychiatric interventions.
These patent filings do not change current treatment options for depression or substance use disorders. It is important to discuss any interest in experimental psychiatric treatments exclusively with a licensed psychiatrist or healthcare provider.
The takeaway
These patent applications are preliminary steps in the development of potential future therapies and do not represent currently available treatments. Patients should continue to rely on evidence-based care and consult with a physician regarding any updates in mental health treatment options.
Further reading
For more on the current research landscape, visit our Substance Abuse section.
Live Poll
Do you trust that combining psychedelic compounds with other drugs will create safer mental health treatments?
